Mapmygenome buys Canada's dnaPower to build out North American testing platform
What's the deal? MapmygenomeDealroom has a profile for this one. Try Dealroom → has completed its acquisition of Vancouver-based dnaPower Inc.Dealroom has a profile for this one. Try Dealroom →, a consumer personal-genomics company founded in 2008. The deal value was undisclosed. It expands Mapmygenome's North American footprint across DNA testing, gut microbiome health, longevity, and AI-driven multi-omics testing.
Who are they? dnaPower specialises in DNA-based health, nutrition, fitness, and longevity insights for consumers and practitioners. Mapmygenome is a personal-genomics company offering whole-genome sequencing, pharmacogenetics, and preventive-health testing.
What's the endgame? Mapmygenome plans to fold dnaPower into a centralised Vancouver processing hub for DNA, microbiome, pharmacogenetic, and longevity testing serving Canada and the US. The hub will run under CAP-accredited and ISO-certified protocols.
Why now? The deal builds on Mapmygenome's 2025 acquisition of Vancouver's Microbiome InsightsDealroom has a profile for this one. Try Dealroom →, which brought it a Canadian lab and microbiome-sequencing expertise. Together, the two deals point to a deliberate push to assemble a North American platform spanning genetics and microbiome testing.
What they're saying: "Acquiring dnaPower is a pivotal step in scaling our North American operations," said Anu Acharya, founder and chief executive officer of Mapmygenome. dnaPower founder and chief executive officer Lois Nahirney said joining Mapmygenome gives it "the foundation to scale rapidly across North America."
The signal: The transaction extends a wave of consolidation in genetic testing — Tempus bought Ambry GeneticsDealroom has a profile for this one. Try Dealroom → in 2025, while 23andMe's consumer assets passed to TTAM Research Institute. Mapmygenome's bet is smaller and more targeted; its payoff hinges on whether the combined portfolio can win meaningful North American customers and research business.
Read more: prnewswire.com
Image credit: Generated with Gemini
